All News

myositis.jpg

Proposed Cancer Screening for Inflammatory Myositis Patients

Jack Cush, MD

Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer.  Abstract 0002 by Oldroyd et al, entitled "Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy" took on this thorny practice issue. 

Read Article
infusion.biologic.jpg

Intravenous Immune Globulin in Dermatomyositis

Jack Cush, MD

Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this pivotal trial.

Read Article
RheumNow Podcast square

RheumNow Podcast – “That’s Not My Name” (10.7.2022)

Jack Cush, MD

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.

Read Article
antibody (Keep)

Clinical Profiles Seen with NXP-2 Antibodies

Jack Cush, MD

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

Read Article
What if my #myositis patient gets pregnant? Abstract #0952 #ACR22 @RheumNow 🫁10 pregnancies ➡️ 1 miscarriage -2 preterm -3 low birth wght -1 HELLP -Mean gestational age 36w 🫁 Higher disease activity ➡️ more adverse pregnancy outcomes

Catherine Sims, MD DrCassySims ( View Tweet)

Key points in managing MDA5+ DM 1. Monitor lungs - HRCT/PFTs 2. Test muscle endurance (ref: IMACS site) not just strength 3. Close observation 4. MTX/MMF initial treatments 5. Repeat muscle biopsy if diagnosis unclear Meet the Expert Lundberg I, IMM session @RheumNow #ACR22 https://t.co/ZVFsYgDBx2
Dr. Antoni Chan synovialjoints ( View Tweet)
Dey @DrMiniDey @ElenaNikiUK @docrota @LatikaGupta_ et al. COVID vaccination in IIM+multimorbidity. Adverse events more common, but still infrequent. Both multimorbidity and active IIM increased risk of AEs. @rheumnow #ACR22 Abstr#0177 https://t.co/HA5NaRrPYL https://t.co/TKtagwa0gG

Links:

Richard Conway RichardPAConway ( View Tweet)
Cancer screening in myositis: the path has always been unclear and inconsistent Workable consensus recommendations @Dr_Alex_Oldroyd risk stratification but still extensive investigation burden for most now need to look at effectiveness including cost ABST0002 #ACR22 @RheumNow https://t.co/322qnGjB9K
David Liew drdavidliew ( View Tweet)
Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositis https://t.co/h1kp7Z9ynO
TheDaoIndex KDAO2011 ( View Tweet)
Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22 @rheumnow #myositis https://t.co/pPLcsFLtG9
TheDaoIndex KDAO2011 ( View Tweet)
Consensus for CA screening in IIM Presented: Risk factors to consider screening #Plenary #ACR22 @rheumnow #myositis https://t.co/CDNPaRUpPS
TheDaoIndex KDAO2011 ( View Tweet)
Risk stratification for cancer in myositis @RheumNow #ACR22 #Plenary https://t.co/j7R7P3PS7c
Julian Segan JulianSegan ( View Tweet)
Some suggested screening tests for malignancy in myositis. Recommendations based on assessment of risk factors @RheumNow #ACR22 #Plenary https://t.co/B0eASeo8hG
Julian Segan JulianSegan ( View Tweet)
A #myositis discussion will not be complete without a slide on myositis antibodies - @JuliePaikMD Great review slide for trainees! #ACR22 @Rheumnow #RheumTwitter @rheumarhyme @PhRheumaJr @doktora_ging https://t.co/e6cB344vH8
sheila RHEUMarampa ( View Tweet)
🔸DM pts who are anti-TIF-1 Ab+ have higher risk of malignancy 🔸Ovarian cancer - most common Really important to do cancer screening in #dermatomyositis #ACR22 @RheumNow https://t.co/jErqcR0Gyr
sheila RHEUMarampa ( View Tweet)
Year in review #ACR22 IVIG received FDA approval for dermatomyositis in 2022! @RheumNow

Bella Mehta bella_mehta ( View Tweet)

Year in Review #ACR22 IVIG received FDA approval for adult dermatomyositis, shows benefit versus placebo First approved Rx for inflammatory myositis ⁦@RheumNow⁩ https://t.co/T6qVTQQdTp
Eric Dein ericdeinmd ( View Tweet)
Clinical Profiles Seen with NXP-2 Antibodies A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer. https://t.co/oCgb1f2Avw https://t.co/rnMa4jHhNy

Links:

Dr. John Cush RheumNow ( View Tweet)
Clinical Profiles Seen with NXP-2 Antibodies A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer. https://t.co/DTNohe66n1 https://t.co/Bu1qbi5Q1q

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR/ACR Classification in MDA5+ Myositis Patients A current analysis suggests that nearly 30% of MDA5 IIM patients may be missed by the 2017 EULAR/ACR classification criteria for IIM. https://t.co/rS25rL5fGO https://t.co/Yw7sGmPW5G

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×